In the final webinar of the 2022 SEA NSCLC Academy, leading international and regional experts debated on:

• WHAT the recent advances are in treating KRAS G12C-mutated NSCLC in second line setting
• WHY KRAS G12C inhibitors may offer a treatment option for patients with KRAS mutation
• HOW management plan for KRAS G12C-mutated NSCLC may be optimised from diagnosis to treatment

Watch the videos below and learn the application of the latest advances in cancer science to the clinical practice in Southeast Asia and Hong Kong.